Ponatinib acts against the most resistant types of chronic myeloid leukemia
A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.
Nov 28, 2012
0
0